SKL2001

• Description :

  SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Wnt; β-catenin

• Type :

  Reference compound

• Related Pathways :

  Stem Cell/Wnt

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SKL2001.html

• Concentration :

  10mM

• Purity :

  99.68

• Solubility :

  DMSO : ≥ 96.66 mg/mL

• Smiles :

  O=C(C1=NOC(C2=CC=CO2)=C1)NCCCN3C=CN=C3

• Molecular Formula :

  C14H14N4O3

• Molecular Weight :

  286.29

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Gwak J, et al. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation. ell Res. 2012 Jan;22 (1) :237-47.|[2]Ohashi W, et al. SKL2001 suppresses colon cancer spheroid growth through regulation of the E-cadherin/β-Catenin complex. Biochem Biophys Res Commun. 2017 Nov 25;493 (3) :1342-1348.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [909089-13-0]